Rivaroxaban in the Prevention of Stroke and Systemic Embolism in Patients with Non-Valvular Atrial Fibrillation: Clinical Implications of the ROCKET AF Trial and Its Subanalyses

Overview of attention for article published in American Journal of Cardiovascular Drugs, June 2015

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (53rd percentile)

Mentioned by

twitter: 2 X users

googleplus: 1 Google+ user

Citations

dimensions_citation: 15 Dimensions

Readers on

mendeley: 105 Mendeley

Summary X Google+ Dimensions citations

So far, Altmetric has seen 4 X posts from 2 X users, with an upper bound of 7,039 followers.

RT @rspenz: When using neuraxial #anesthesia, guidelines suggest 22–26h between lastdose #rivaroxaban + spinal/epidural puncture https://t.…

Reply Repost Favourite

When using neuraxial #anesthesia, guidelines suggest 22–26h between lastdose #rivaroxaban + spinal/epidural puncture https://t.co/9mVWiKCVum

Reply Repost Favourite

When using neuraxial anesthesia, guidelines recommend 22–26h between last dose rivaroxaban + spinal/epidural puncture http://t.co/9mVWiKCVum

Reply Repost Favourite

Rivaroxaban review: effective, once daily alternative to warfarin for non-valvular #AtrialFibrillation: http://t.co/OoE5GetqEZ

Reply Repost Favourite